In an MS-related mouse model, PACAP ameliorated both clinical and pathologic manifestations of experimental autoimmune encephalomyelitis (EAE), while treatment with VIP reduced incidence and severity of EAE by an anti-inflammatory action (Kato et al., 2004; Fernandez-Martin et al., 2006). This evidence concerns the gene VIP and myeloid sarcoma.